Shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) shot up 3.5% during mid-day trading on Tuesday . The stock traded as high as $3.40 and last traded at $3.25. 66,286 shares were traded during mid-day trading, a decline of 8% from the average session volume of 71,822 shares. The stock had previously closed at $3.14.
Cyclerion Therapeutics Price Performance
The business has a 50-day moving average of $2.89 and a 200 day moving average of $2.86.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
See Also
- Five stocks we like better than Cyclerion Therapeutics
- Energy and Oil Stocks Explained
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Canadian Penny Stocks: Can They Make You Rich?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
